To bolster its diabetes portfolio in India, multinational pharmaceutical giant Lupin Limited announced the purchase of the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim International GmbH (Boehringer Ingelheim).
By March of next year, Lupin will receive the trademark rights for these brands in accordance with the conditions of the agreement. Through current co-marketing agreements with Boehringer Ingelheim India, Lupin has been marketing GIBTULIO and GIBTULIO MET in the Indian market since 2016 and AJADUO since 2018.
AJADUO (empagliflozin + linagliptin), GIBTULIO (empagliflozin), and GIBTULIO MET (empagliflozin + metformin) are members of a new class of oral anti-diabetic medications called sodium glucose co-transporter-2 (SGLT-2) inhibitors (and combinations). In addition to diet and exercise, they are recommended to help persons with type 2 diabetes mellitus achieve better glycemic control,” the business said in a statement.
According to the statement, empagliflozin is also recommended to lower the risk of cardiovascular death in individuals with type 2 diabetes and the risk of heart failure hospitalization and cardiovascular death in adults with chronic renal disease.
“Lupin has always been in the forefront of offering patients top-notch medical care options. Nilesh Gupta, Managing Director, Lupin, stated, “This purchase is a significant step in improving our diabetic portfolio and reinforces our commitment to offering innovative and cost-effective pharmaceuticals for patients across India.”
In India, an estimated 80 million adults over the age of 18 have diabetes, and another 25 million are pre-diabetic. Diabetes is not well known; over 50% of individuals do not know they have the disease, which can cause several health issues if it is not identified and treated in a timely manner. Heart attacks and strokes are more likely to occur in adults with diabetes.
“The rising incidence of diabetes and associated lifestyle disorders necessitates a stronger focus on diabetes treatment and management, as well as patient access to medications,” stated Rajeev Sibal, President – India Region Formulations, Lupin, in response to the purchase. We can now provide millions of people in India with efficient and reasonably priced treatment alternatives thanks to this acquisition.
-Raja Aditya
